title: Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma.
abstract: OBJECTIVE
  To examine the usefulness of various receptor tyrosine kinase expressions as prognostic markers and therapeutic targets in muscle invasive urothelial cancer (UC) patients.
  
  
  METHODS
  We retrospectively analyzed the data of 98 patients with muscle invasive UC who underwent radical cystectomy between 2005 and 2010 in Yonsei Cancer Center. Using formalin fixed paraffin embedded tissues of primary tumors, immunohistochemical staining was done for human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor 1 (FGFR1), and fibroblast growth factor receptor 3 (FGFR3).
  
  
  RESULTS
  There were 41 (41.8%), 44 (44.9%), and 14 (14.2%) patients who have over-expressed HER2, FGFR1, and FGFR3, respectively. In univariate analysis, significantly shorter median time to recurrence (TTR) (12.9 months vs. 49.0 months; p=0.008) and overall survival (OS) (22.3 months vs. 52.7 months; p=0.006) was found in patients with FGFR1 overexpression. By contrast, there was no difference in TTR or OS according to the HER2 and FGFR3 expression status. FGFR1 remained as a significant prognostic factor for OS with hazard ratio of 2.23 (95% confidence interval: 1.27-3.90, p=0.006) in multivariate analysis.
  
  
  CONCLUSIONS
  Our result showed that FGFR1 expression, but not FGFR3, is an adverse prognostic factor in muscle invasive UC patients after radical cystectomy. FGFR1 might be feasible for prognosis prediction and a potential therapeutic target after thorough validation in muscle invasive UC.
authors.affiliation: Department of Internal Medicine, Wonju Severance Christian Hospital, Wonju, Korea.|Department of Medicine, Graduate School of Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Seungtaek
authors.initials: S
authors.lastname: Lim
authors.affiliation: Department of Pathology, Daedong Hospital, Busan, Korea.
authors.forename: Myoung Ju
authors.initials: MJ
authors.lastname: Koh
authors.affiliation: Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Hyeon Joo
authors.initials: HJ
authors.lastname: Jeong
authors.affiliation: Department of Medicine, Graduate School of Yonsei University College of Medicine, Seoul, Korea.|Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Nam Hoon
authors.initials: NH
authors.lastname: Cho
authors.affiliation: Department of Medicine, Graduate School of Yonsei University College of Medicine, Seoul, Korea.|Department of Urology, Yonsei University College of Medicine, Seoul, Korea.|Yonsei Cancer Center, Yonsei University Health System, Seoul, Korea.
authors.forename: Young Deuk
authors.initials: YD
authors.lastname: Choi
authors.affiliation: Department of Hematology and Oncology, Konyang University College of Medicine, Daejeon, Korea.
authors.forename: Do Yeun
authors.initials: do Y
authors.lastname: Cho
authors.affiliation: Department of Pharmacology, Myunggok Medical Research Institute, College of Medicine, Konyang University, Daejeon, Korea.
authors.forename: Hoi Young
authors.initials: HY
authors.lastname: Lee
authors.affiliation: Department of Medicine, Graduate School of Yonsei University College of Medicine, Seoul, Korea.|Yonsei Cancer Center, Yonsei University Health System, Seoul, Korea.|Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.|Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea. rha7655@yuhs.ac.
authors.forename: Sun Young
authors.initials: SY
authors.lastname: Rha
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000378:metabolism* / Q000401:mortality* / Q000601:surgery; D015653:Cystectomy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009132:Muscles / Q000473:pathology; D009361:Neoplasm Invasiveness; D011379:Prognosis; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000378:metabolism*; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000378:metabolism; D012189:Retrospective Studies; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000601:surgery; D019459:Urothelium / Q000473:pathology
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D051496:Receptor, Fibroblast Growth Factor, Type 1; D051498:Receptor, Fibroblast Growth Factor, Type 3; C508053:ERBB2 protein, human; C496348:FGFR1 protein, human; C496365:FGFR3 protein, human
keywords: Urinary bladder neoplasms; cystectomy; prognosis; receptor tyrosine kinases